Neuralgia News and Research

RSS
Neuralgia is pain in one or more nerves that occurs without stimulation of pain receptor (nociceptor) cells. Neuralgia pain is produced by a change in neurological structure or function rather than by the excitation of pain receptors that causes nociceptive pain.
Novel substance can effectively inhibit chronic nerve pain, study shows

Novel substance can effectively inhibit chronic nerve pain, study shows

Neurologists identify cause of immune-mediated neuropathies

Neurologists identify cause of immune-mediated neuropathies

FDA approves non-alcoholic Docetaxel Injection

FDA approves non-alcoholic Docetaxel Injection

Nuvo Research announces topline results from WF10 Phase 2 trial for treatment of allergic rhinitis

Nuvo Research announces topline results from WF10 Phase 2 trial for treatment of allergic rhinitis

Shingles vaccine can help protect elderly patients with end-stage renal disease

Shingles vaccine can help protect elderly patients with end-stage renal disease

Delaying stereotactic radiosurgery worsens trigeminal neuralgia pain outcomes

Delaying stereotactic radiosurgery worsens trigeminal neuralgia pain outcomes

Psychiatric disorders may follow trigeminal neuralgia

Psychiatric disorders may follow trigeminal neuralgia

Study: Chickenpox vaccination increases incidence of shingles in younger adults

Study: Chickenpox vaccination increases incidence of shingles in younger adults

Mylan announces launch of Lidocaine Patch 5% in the U.S.

Mylan announces launch of Lidocaine Patch 5% in the U.S.

First patient enrolled in Contravir‘s FV-100 Phase 3 study to prevent shingles, shingles-associated pain

First patient enrolled in Contravir‘s FV-100 Phase 3 study to prevent shingles, shingles-associated pain

Spinifex Pharmaceuticals enters into agreement to be acquired by Novartis

Spinifex Pharmaceuticals enters into agreement to be acquired by Novartis

Immune Pharmaceuticals begins bertilimumab Phase II clinical trials in Bullous Pemphigoid, Ulcerative Colitis

Immune Pharmaceuticals begins bertilimumab Phase II clinical trials in Bullous Pemphigoid, Ulcerative Colitis

Findings could lead to treatments for chronic pain caused by nerve damage

Findings could lead to treatments for chronic pain caused by nerve damage

Baruch S. Blumberg Institute engaged to conduct study using ContraVir's new HBV therapeutic candidate

Baruch S. Blumberg Institute engaged to conduct study using ContraVir's new HBV therapeutic candidate

Immune Pharmaceuticals announces Q1 2015 financial results; files Quarterly Report on Form 10-Q

Immune Pharmaceuticals announces Q1 2015 financial results; files Quarterly Report on Form 10-Q

Brainlab launches automated stereotactic radiosurgery planning tools at ESTRO 2015

Brainlab launches automated stereotactic radiosurgery planning tools at ESTRO 2015

Depomed acquires U.S. rights to NUCYNTA franchise from Janssen Pharmaceuticals

Depomed acquires U.S. rights to NUCYNTA franchise from Janssen Pharmaceuticals

TPU's submission of Docetaxel Injection Concentrate, Non-Alcohol Formula NDA acknowledged by FDA

TPU's submission of Docetaxel Injection Concentrate, Non-Alcohol Formula NDA acknowledged by FDA

ContraVir granted Type B meeting with FDA to discuss proposal for FV-100 Phase 3 trial

ContraVir granted Type B meeting with FDA to discuss proposal for FV-100 Phase 3 trial

ContraVir begins pharmacokinetic study of FV-100 for treating shingles

ContraVir begins pharmacokinetic study of FV-100 for treating shingles